AxSYM 항-Cyclic Citrullinated Peptide 항체 검사의 진단적 유용성 평가
Diagnostic Utility of AxSYM Anti-Cyclic Citrullinated Peptide Antibody Assay
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Background : The presence of rheumatoid factor (RF) is one of the classification criteria of the American College of Rheumatology (ACR) for rheumatoid arthritis (RA), but it has a limitation of low specificity. We compared the diagnostic utility of anti-cyclic citrullinated peptide (CCP) antibodies analyzed by an automated immunoassay system with that measured by a 96 well plate ELISA method. Methods : The RF and anti-CCP antibodies were determined in 172 serum samples: 52 RA patients, 73 disease controls (systemic lupus, Sjogren’s syndrome, palindromic rheumatism), and 47 healthy controls. Anti-CCP antibodies were measured by DIASTAT 96 well plate ELISA method (Axis-Shield Diagnostics, UK) and AxSYM automated microparticle enzyme immunoassay system (Abbott Laboratories, USA). RF was assayed by latex immunoturbidimetry (Toshiba 200 FR, Japan). The diagnostic performances of these tests were compared using a ROC curve analysis, and linearity and precision analysis of AxSYM anti-CCP was carried out. Results : The sensitivities of RF, DIASTAT anti-CCP, and AxSYM anti-CCP were 78.8%, 84.6%, and 82.7%, respectively and the specificities were 72.5%, 88.3%, and 88.3%, respectively. On ROC curve analysis, the area under the curve was 0.924 for AxSYM anti-CCP, 0.886 for DIASTAT anti-CCP, and 0.847 for RF. AxSYM anti-CCP showed a good linearity, and within-run and total-run precision. Conclusions : Diagnostic performance of automated AxSYM anti-CCP assay was comparable to that of DIASTAT 96 well plate ELISA method. AxSYM anti-CCP assay has an advantage of random access capability and will be useful in laboratories with low sample number and/or with a need of rapid turnaround time. (Korean J Lab Med 2008;28:457-64)
참고문헌 (21)
- Kasper DL, "Harrison’s principles of internal medicine", pp.1968~1976 (2004), McGraw-Hill
- Boers M, "Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis", Lancet, 350, pp.309~318 (1997)
- Anderson JJ, "Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration", Arthritis Rheum, 43, pp.22~29 (2000)
- Steiner G, "Autoantibodies in rheumatoid arthritis and their clinical significance", Arthritis Res, 4(S), pp.S1~S15 (2002)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Schellekens GA, "The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide", Arthritis Rheum, 43, pp.155~163 (2000)
- van Boekel MA, "Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value", Arthritis Res, 4, pp.87~93 (2002)
- Nishimura K, "Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis", Ann Intern Med, 146, pp.797~808 (2007)
- Clinical and Laboratory Standards Institute, "Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline" (2003), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Evaluation of precision performance of quantitative measurement methods; approved guideline-2nd edi" (2004), Clinical and Laboratory Standards Institute
- Newkirk MM., "Rheumatoid factors: host resistance or autoimmunity?", Clin Immunol, 104, pp.1~13 (2002)
- Avouac J, "Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review", Ann Rheum Dis, 65, pp.845~851 (2006)
- Nielen MM, "Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors", Arthritis Rheum, 50, pp.380~386 (2004)
- van Oosterhout M, "Differences in synovial tissue infiltrates between anticyclic citrullinated peptide-positive rheumatoid arthritis and anticyclic citrullinated peptide-negative rheumatoid arthritis", Arthritis Rheum, 58, pp.53~60 (2008)
- Liao KP, "Anticyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis", Ann Rheum Dis, 67, pp.1557~1561 (2008)
- Lutteri L, "Comparison of second- and thirdgeneration anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis", Clin Chim Acta, 386, pp.76~81 (2007)
- Coenen D, "Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein", peptide antibodies in the diagnosis of rheumatoid arthritis, 2007, pp.53, 498~504
- 조선영1, "류마티스 관절염 진단에 있어서 항-Cyclic Citrullinated Peptide 항체와류마티스인자의 진단적 가치 비교 평가", The Korean Journal of Laboratory Medicine, 28(1), pp.39~45 (2008), 대한진단검사의학회
- Salvador G, "Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?", Rheumatology, 42, pp.972~975 (2003)
- Russell AS, "The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palin-dromic rheumatism to rheumatoid arthritis", J Rheumatol, 33, pp.1240~1242 (2006)
- Chan MT, "Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus", J Rheumatol, 35, pp.77~83 (2008)